查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1736740

全球 CRISPR 和 Cas 基因市场规模（按类型、应用、最终用户、区域范围和预测）

Global CRISPR And Cas Genes Market Size By Type, By Application, By End-User, By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

CRISPR和Cas基因的市场规模和预测

2024 年 CRISPR 和 Cas 基因市场规模价值 29.0305 亿美元，预计到 2032 年将达到 88.6198 亿美元，2026 年至 2032 年的复合年增长率为 14.97%。

CRISPR（成簇规律间隔短回文重复序列）和 Cas（CRISPR 相关）基因是革命性的基因编辑工具。 CRISPR 是细菌的一种天然防御机制，可以识别和切割外来 DNA，而 Cas 蛋白（例如 Cas9）则可作为分子剪刀进行切割。该技术已被开发用于多种生物体，可实现精确的基因序列修饰。其应用包括用于改善遗传问题的基因治疗、用于提高作物抗性和产量的农业生物技术，以及透过标靶疾病相关基因开发新型治疗方法。

CRISPR 和 Cas 基因应用广泛，前景看好。这项技术的进步有望推动个人化医疗的突破，届时基因药物可以根据个体的基因图谱进行定制，从而实现疗效最大化。 CRISPR 精准度和递送机制的创新有望扩大其在治疗癌症和罕见遗传疾病等复杂疾病方面的应用。

此外，CRISPR技术有望促进合成生物学的发展，使生产具有独特功能的基因改造生物成为可能。伦理问题和法律体制对于塑造这些进步并确保其负责任地实施至关重要。

CRISPR 和 Cas 基因的全球市场动态

影响全球 CRISPR 和 Cas 基因市场的关键市场动态是：

关键市场驱动因素

基因异常盛行率的不断上升：基因异常盛行率的不断上升是CRISPR和Cas基因市场的主要驱动力。世界卫生组织（WHO）报告称，约有1万种人类疾病本质上是一次性的。根据全球基因计画的数据，全球有3亿人患有罕见疾病，其中大多数是遗传性疾病。如此庞大的患者族群对CRISPR等基因编辑技术的需求庞大，可用于潜在的治疗。

基因组学研究投入不断增加：随着基因编辑技术的加速发展，CRISPR 和 Cas 基因市场也将蓬勃发展。 2016 年至 2020 年期间，美国政府将为基因组学研究投入超过 38 亿美元，而英国医学研究委员会将在 2022 年投入 2 亿英镑。这笔巨额资金正在推动创新、大规模研究以及基于 CRISPR 的药物开发，使其成为市场成长的重要因素。

农业和食品生产领域应用不断拓展：CRISPR 技术正在推动农业领域的突破，透过提高作物产量和培育健壮的植物品种来满足日益增长的全球粮食需求。联合国粮食及农业组织 (FAO) 预测，到 2050 年，农业生产力将提高 60%，CRISPR 已广受认可。 2019 年《自然·植物》杂誌的一篇论文指出，CRISPR 编辑的作物已在 20 多个国家种植。 CRISPR 在农业领域的应用不断拓展，有助于促进粮食安全和永续性，使其成为市场的关键驱动力。

主要问题

伦理担忧：CRISPR技术的使用引发了重大的伦理担忧，尤其是在生殖细胞编辑及其意外后果方面。编辑人类胚胎并进行可能遗传给后代的修改，引发了人们对其可能对人类遗传学产生长期影响的担忧。这些伦理担忧可能会导致监管延迟并影响公众认知，从而降低对CRISPR解决方案的接受度和投资。

研发成本：开发和商业化基于 CRISPR 的技术需要大量的研发成本。创新、合规和临床试验相关的高昂成本，可能会使小型企业和研究机构难以在市场上竞争。这一高昂的成本阻碍了技术进步，并降低了基于 CRISPR 的治疗方法的可及性。

生物安全风险：CRISPR 技术被滥用的可能性引发了生物安全担忧，包括危险的基因改造和生物武器的研发。为了避免此类担忧，必须以负责任的方式使用 CRISPR 技术，并采取适当的安全措施。解决生物安全问题对于该技术的可靠性和安全性至关重要。

主要趋势

更高的精度和效率：近期的进展，包括Cas9的增强变体以及新型CRISPR相关系统的引入，显着提高了CRISPR技术的精度和效率。这些进展提高了编辑的准确性，同时减少了脱靶效应，使CRISPR在治疗应用上更加可靠。对更精准基因编辑的需求促进了相关研究和临床试验，增强了该技术治疗遗传性疾病和其他疾病的潜力。

农业生物技术的发展：CRISPR正被用于培育基因改造作物，使其具有产量、抗病和抗逆等特性。精准修改基因的能力促进了其在农业研究的应用。这一趋势正在促进永续农业技术的发展，改善粮食安全，并在农业领域引发巨大的兴趣和投资。

不断发展的伦理和监管框架：更清晰的伦理原则和法律规范使负责任地采用 CRISPR 技术变得更加容易。随着法规变得更加清晰，研究人员和公司对 CRISPR 的可接受用途有了更深入的了解，从而促进了其融入临床实践和商业产品。这一趋势正在支持 CRISPR 市场的信任和成长。

新型 CRISPR 系统的出现：除 Cas9 之外，CRISPR/Cas12 和 CRISPR/Cas13 等新型 CRISPR 系统正在被发现和开发中。这些创新系统具有独特的特性和应用，例如更少的脱靶效应和更佳的标靶性。对这些系统的探索正在推动创新，拓展 CRISPR 技术的潜在应用，从而支持市场的成长。

目录

第一章 全球 CRISPR 与 Cas 基因市场简介

  • 市场概览
  • 研究范围
  • 先决条件

第 2 章 已验证的市场研究调查方法

  • 资料探勘
  • 二次研究
  • 初步研究
  • 专家建议
  • 品质检查
  • 最终审核
  • 数据三角测量
  • 自下而上的方法
  • 自上而下的方法
  • 调查流程
  • 资料来源

第三章执行摘要

  • 概述
  • 绝对的商机
  • 市场吸引力
  • 未来市场机会

第四章 CRISPR 和 Cas 基因的全球市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

5. 全球 CRISPR 和 Cas 基因市场（按类型）

  • 概述
  • 无DNA Cas
  • 基于载体的Cas

6. 全球 CRISPR 和 Cas 基因市场（按应用）

  • 概述
  • 基因组工程
  • 功能基因体学
  • 疾病模型
  • 其他的

7. 全球 CRISPR 和 Cas 基因市场（按最终用户）

  • 概述
  • 生物技术和製药公司
  • 学术和政府研究机构
  • 受託研究机构

8. 全球 CRISPR 和 Cas 基因市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 其他的
    • 拉丁美洲
    • 中东和非洲

9.全球CRISPR和Cas基因市场竞争格局

  • 概述
  • 各公司市场排名
  • 重点发展策略
  • 公司地理分布
  • 公司产业布局
  • ACE矩阵

第十章 公司简介

  • OriGene Technologies, Inc
  • Thermo Fisher Scientific
  • Takara Bio Inc.
  • Horizon Discovery Ltd.
  • Addgene
  • Merck KGaA
  • Caribou Biosciences, Inc.
  • CRISPR THERAPEUTICS
  • Editas Medicine
  • Mirus Bio LLC.

第十一章 重大进展

  • 产品发布/开发
  • 合併与收购
  • 业务扩展
  • 伙伴关係与合作

第十二章 附录

  • 相关调查
简介目录
Product Code: 40530

CRISPR And Cas Genes Market Size And Forecast

CRISPR And Cas Genes Market size was valued at USD 2903.05 Million in 2024 and is projected to reach USD 8861.98 Million by 2032, growing at a CAGR of 14.97% from 2026 to 2032.

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and Cas (CRISPR-associated) genes are revolutionary genetic editing tools. CRISPR is a natural defense mechanism in bacteria that identifies and cuts foreign DNA, while Cas proteins, such as Cas9, operate as molecular scissors to perform these cuts. This technique has been developed for application in a wide range of organisms, allowing for precise genetic sequence modifications. Gene therapy to rectify genetic problems, agricultural biotechnology to improve crop resistance and productivity, and the creation of novel treatments by targeting disease-associated genes are among the various uses.

The CRISPR and Cas genes are extensive and promising. Advances in this technique are likely to lead to breakthroughs in personalized medicine, with genetic medicines customized to individual genetic profiles for maximum efficacy. Innovations in CRISPR precision and delivery mechanisms are likely to expand its use in the treatment of complicated diseases such as cancer and rare genetic abnormalities.

Furthermore, CRISPR technology is expected to propel advances in synthetic biology, allowing the production of modified creatures with unique functions. Ethical issues and legal frameworks will be critical in directing these advancements and guaranteeing their responsible implementation.

Global CRISPR And Cas Genes Market Dynamics

The key market dynamics that are shaping the global CRISPR And Cas Genes Market include:

Key Market Drivers:

Increasing Prevalence of Genetic Disorders: The increasing prevalence of genetic abnormalities is a primary driver of the CRISPR And Cas Genes Market. The World Health Organization (WHO) reports that roughly 10,000 human disorders are monogenic. According to the Global Genes Project, 300 million people worldwide suffer from rare diseases, the majority of which are hereditary. This large patient population generates a high demand for gene-editing technologies such as CRISPR for possible treatments.

Rising Investments in Genomics Research: The CRISPR And Cas Genes Market forward by speeding advances in gene-editing technologies. From 2016 to 2020, the US government financed more than $3.8 billion on genomics research, with the UK's Medical Research Council committing £200 million in 2022. This enormous funding promotes innovation, large-scale studies, and the development of CRISPR-based medicines, making it an essential factor in market growth.

Expanding Applications in Agriculture and Food Production: CRISPR technology is driving breakthroughs in agriculture by boosting crop yields and developing robust plant varieties to fulfill rising global food demand. With the Food and Agriculture Organization (FAO) anticipating a 60% increase in agricultural productivity by 2050, CRISPR is being extensively embraced, as indicated by a 2019 article in Nature Plants, which found CRISPR-edited crops grown in over 20 nations. This growing application of CRISPR in agriculture promotes food security and sustainability, making it an important driver in the market.

Key Challenges:

Ethical Concerns: The use of CRISPR technology presents significant ethical concerns, notably about germline editing and its unintended consequences. Editing human embryos or making alterations that may be inherited by future generations raises concerns about the implications over time for human genetics. These ethical considerations can cause regulatory delays and influence public perception, reducing acceptance and investment in CRISPR-based solutions.

Cost of Research and Development: Developing and commercializing CRISPR-based technologies incurs enormous R&D costs. The high costs associated with innovation, regulatory compliance, and clinical trials can make it difficult for smaller enterprises and research institutes to compete in the market. This costly hurdle hinders progress and reduces the availability of CRISPR-based therapies.

Biosecurity Risks: The possible misuse of CRISPR technology raises biosecurity concerns, such as the development of risky genetic changes or bioweapons. To avoid these concerns, CRISPR technology must be utilized responsibly and with proper protections in place. Addressing biosecurity concerns is critical for the technology's credibility and safe use.

Key Trends:

Precision and Efficiency Advancements: Recent developments, including enhancements in Cas9 variations and the introduction of new CRISPR-associated systems, have considerably improved CRISPR technology's precision and efficiency. These developments lessen off-target effects while increasing editing accuracy, making CRISPR more trustworthy for therapeutic applications. The desire for more precise gene editing is fueling research and clinical trials, increasing the technology's promise for treating genetic abnormalities and other diseases.

Growth in Agricultural Biotechnology: CRISPR is being used to generate genetically modified crops with enhanced features such as increased yield, disease resistance, and stress tolerance. The technology's capacity to make precise genetic changes is pushing its use in agricultural research. This trend promotes sustainable farming techniques and improves food security, generating major interest and investment in the agriculture sector.

Advancement in Ethical and Regulatory Frameworks: Clearer ethical principles and regulatory frameworks are making it easier to employ CRISPR technology responsibly. As rules become more defined, researchers and businesses acquire a greater understanding of the acceptable use of CRISPR, facilitating its integration into clinical practice and commercial products. This tendency is boosting confidence and growth in the CRISPR market.

Emergence of Novel CRISPR Systems: The discovery and development of novel CRISPR systems beyond Cas9, such as CRISPR/Cas12 and CRISPR/Cas13, is ongoing. These innovative systems have distinct traits and applications, including fewer off-target impacts and increased targeting capabilities. Exploration of these systems drives innovation and broadens the possible applications of CRISPR technology, hence supporting market growth.

Global CRISPR And Cas Genes Market Regional Analysis

Here is a more detailed regional analysis of the global CRISPR And Cas Genes Market:

North America:

North America remains a dominant player in the CRISPR And Cas Genes Market, owing to its strong research infrastructure and advanced biotechnology sector. The region's best research institutes and universities are critical to CRISPR innovation, with NIH funding increasing from USD 5.1 Million in 2011 to more than USD 603 Million in 2020, representing an unparalleled 11,725% growth. This flood of funding has resulted in a 27% annual increase in CRISPR-related publications from North American institutions, as reported by PubMed in 2022. Complementing this, North America's well-established biotechnology industry, which includes over 6,500 biotech firms in the United States, with around 12% focusing on gene editing, drives significant progress.

The region's favorable regulatory framework also helps to advance CRISPR research and commercialization. The FDA has accepted 23 Investigational New Drug (IND) applications for CRISPR-based therapies as of 2024, a 53% increase over 2020. Since 2019, the Regenerative Medicine Advanced Therapy (RMAT) designation has advanced the approval of five CRISPR-based therapeutics.

The growing number of active CRISPR-related clinical trials, which will reach 152 in North America by September 2024, a 36% increase over the previous year, illustrates CRISPR's expanding therapeutic applicability, notably in oncology. These factors contribute to North America's leadership and continuous innovation in the CRISPR And Cas Genes Market.

Asia Pacific:

The CRISPR And Cas Genes Market in Asia Pacific is expanding rapidly, owing to significant investments, increased research activity, and a big population base. Governments in the area are making considerable expenditures in biotechnology and healthcare, with biotechnology investments increasing by 32% between 2018 and 2022, according to the Asia Pacific Economic Cooperation. China has committed USD 9.2 Billion to its precision medicine project, which includes significant funding for CRISPR technology, while Japan's genome editing consumption has increased by 41% between 2019 and 2024. This funding backing has sped up the development of CRISPR-based solutions and technologies.

The Asia Pacific area has strong financial backing, vigorous research activity, and a large population, all of which fuel demand for CRISPR applications. Research institutes have dramatically boosted their contributions to CRISPR investigations, with Asia Pacific publications increasing by 28% annually between 2018 and 2022. The region's massive population, predicted to reach 4.7 billion by 2025, opens up numerous prospects for CRISPR in healthcare and agriculture. For instance, 12 Asian countries are developing CRISPR-edited crops, with field trials increasing by 45% between 2020 and 2024. The number of CRISPR-related clinical trials in Asia Pacific increased by 140% between 2019 and 2024, demonstrating the region's growing importance in worldwide CRISPR breakthroughs and applications.

Global CRISPR And Cas Genes Market: Segmentation Analysis

The Global CRISPR And Cas Genes Market is Segmented on the basis of Type, Application, End-User, And Geography.

CRISPR And Cas Genes Market, By Type

  • DNA-Free Cas
  • Vector-Based Cas

Based on Type, the market is bifurcated into DNA-free Cas and Vector-based Cas. The CRISPR and Cas gene market is currently dominated by vector-based Cas systems, which use viral vectors to deliver the Cas gene to cells. This method has been widely utilized due to its effectiveness and versatility. DNA-free Cas systems, which use non-viral delivery techniques, are becoming the most rapidly developing sector. These systems have advantages such as fewer off-target effects and larger safety, making them appealing for therapeutic applications. As research and development in DNA-free Cas delivery progresses, it is projected to capture considerable market share in the years ahead.

CRISPR And Cas Genes Market, By Application

  • Genome Engineering
  • Functional Genomics
  • Disease Models

Based on Application, the market is segmented into Genome Engineering, Functional Genomics, and Disease Models. The CRISPR And Cas Genes Market is currently dominated by genome engineering applications, which include changing organisms' genetic code for a variety of reasons. This segment has grown significantly due to its ability to solve a wide range of difficulties, such as disease treatment, crop improvement, and biofuel generation. Functional genomics, which examines gene function and connections, is emerging as the most rapidly increasing segment. As researchers develop a better grasp of gene biology, functional genomics applications grow, increasing demand for CRISPR-based tools and techniques.

CRISPR And Cas Genes Market, By End-User

  • Biotechnology & Pharmaceutical Companies
  • Academic & Government Research Institutes
  • Contract Research Organizations

Based on End-User, the market is segmented into Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, and Contract Research Organizations. Biotechnology and pharmaceutical businesses now dominate the CRISPR and Cas gene market, using this technology for drug discovery, development, and therapeutic applications. These firms have significant resources and competence in translating CRISPR research into commercial goods. Academic institutions and government research institutes are emerging as the most rapidly rising area. These institutions play an important role in fundamental research, promoting innovation, and improving the area of CRISPR. Their findings are frequently used to develop commercial applications, making them important contributors to market growth.

Key Players

The "Global CRISPR And Cas Genes Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are OriGene Technologies, Inc., Thermo Fisher Scientific, Takara Bio, Inc., Horizon Discovery Ltd., Addgene, Merck KGaA, Caribou Biosciences, Inc., CRISPR therapeutics, Editas Medicine and Mirus Bio LLC. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

  • CRISPR And Cas Genes Market Recent Developments
  • In June 2024, DNA nanobots, a biotechnology business, stated that it completed gene editing technology developed at the University of California (UC) Berkeley. The licensed intellectual property allows for the folding of genes into their own delivery devices, in conjunction with CRISPR-Cas, to provide very efficient non-viral gene delivery.
  • In April 2024, Caszyme, a biotech company based in Lithuania that develops CRISPR gene-editing technology, plans to construct a new facility. The expansion seeks to help create non-complementary competencies to fulfill the growing demand for gene-editing-based systems and products across Asia, Europe, and the United States.
  • In November 2022, Researchers at the Massachusetts Institute of Technology developed PASTE, a new CRISPR-based technology that inserts huge DNA sequences at targeted places in cells. The approach has the potential to treat a wide range of diseases caused by defective genes.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL CRISPR AND CAS GENES MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 2.1 Data mining
  • 2.2 Secondary research
  • 2.3 Primary research
  • 2.4 Subject matter expert advice
  • 2.5 Quality check
  • 2.6 Final review
  • 2.7 Data triangulation
  • 2.8 Bottom-up approach
  • 2.9 Top-down approach
  • 2.10 Research flow
  • 2.11 Data sources

3 EXECUTIVE SUMMARY

  • 3.1 Overview
  • 3.2 Absolute $ Opportunity
  • 3.3 Market attractiveness
  • 3.4 Future Market Opportunities

4 GLOBAL CRISPR AND CAS GENES MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL CRISPR AND CAS GENES MARKET, BY TYPE

  • 5.1 Overview
  • 5.2 DNA-free Cas
  • 5.3 Vector-based Cas

6 GLOBAL CRISPR AND CAS GENES MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Genome Engineering
  • 6.3 Functional Genomics
  • 6.4 Disease Models
  • 6.5 Others

7 GLOBAL CRISPR AND CAS GENES MARKET, BY END-USER

  • 7.1 Overview
  • 7.2 Biotechnology & Pharmaceutical Companies
  • 7.3 Academic & Government Research Institutes
  • 7.4 Contract Research Organizations

8 GLOBAL CRISPR AND CAS GENES MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East and Africa

9 GLOBAL CRISPR AND CAS GENES MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies
  • 9.4 Company Regional Footprint
  • 9.5 Company Industry Footprint
  • 9.6 ACE Matrix

10 COMPANY PROFILES

  • 10.1 OriGene Technologies, Inc
    • 10.1.1 Company Overview
    • 10.1.2 Company Insights
    • 10.1.3 Business Breakdown
    • 10.1.4 Product Benchmarking
    • 10.1.5 Key Developments
    • 10.1.6 Winning Imperatives
    • 10.1.7 Current Focus & Strategies
    • 10.1.8 Threat from Competition
    • 10.1.9 SWOT Analysis
  • 10.2 Thermo Fisher Scientific
    • 10.2.1 Company Overview
    • 10.2.2 Company Insights
    • 10.2.3 Business Breakdown
    • 10.2.4 Product Benchmarking
    • 10.2.5 Key Developments
    • 10.2.6 Winning Imperatives
    • 10.2.7 Current Focus & Strategies
    • 10.2.8 Threat from Competition
    • 10.2.9 SWOT Analysis
  • 10.3 Takara Bio Inc.
    • 10.3.1 Company Overview
    • 10.3.2 Company Insights
    • 10.3.3 Business Breakdown
    • 10.3.4 Product Benchmarking
    • 10.3.5 Key Developments
    • 10.3.6 Winning Imperatives
    • 10.3.7 Current Focus & Strategies
    • 10.3.8 Threat from Competition
    • 10.3.9 SWOT Analysis
  • 10.4 Horizon Discovery Ltd.
    • 10.4.1 Company Overview
    • 10.4.2 Company Insights
    • 10.4.3 Business Breakdown
    • 10.4.4 Product Benchmarking
    • 10.4.5 Key Developments
    • 10.4.6 Winning Imperatives
    • 10.4.7 Current Focus & Strategies
    • 10.4.8 Threat from Competition
    • 10.4.9 SWOT Analysis
  • 10.5 Addgene
    • 10.5.1 Company Overview
    • 10.5.2 Company Insights
    • 10.5.3 Business Breakdown
    • 10.5.4 Product Benchmarking
    • 10.5.5 Key Developments
    • 10.5.6 Winning Imperatives
    • 10.5.7 Current Focus & Strategies
    • 10.5.8 Threat from Competition
    • 10.5.9 SWOT Analysis
  • 10.6 Merck KGaA
    • 10.6.1 Company Overview
    • 10.6.2 Company Insights
    • 10.6.3 Business Breakdown
    • 10.6.4 Product Benchmarking
    • 10.6.5 Key Developments
    • 10.6.6 Winning Imperatives
    • 10.6.7 Current Focus & Strategies
    • 10.6.8 Threat from Competition
    • 10.6.9 SWOT Analysis
  • 10.7 Caribou Biosciences, Inc.
    • 10.7.1 Company Overview
    • 10.7.2 Company Insights
    • 10.7.3 Business Breakdown
    • 10.7.4 Product Benchmarking
    • 10.7.5 Key Developments
    • 10.7.6 Winning Imperatives
    • 10.7.7 Current Focus & Strategies
    • 10.7.8 Threat from Competition
    • 10.7.9 SWOT Analysis
  • 10.8 CRISPR THERAPEUTICS
    • 10.8.1 Company Overview
    • 10.8.2 Company Insights
    • 10.8.3 Business Breakdown
    • 10.8.4 Product Benchmarking
    • 10.8.5 Key Developments
    • 10.8.6 Winning Imperatives
    • 10.8.7 Current Focus & Strategies
    • 10.8.8 Threat from Competition
    • 10.8.9 SWOT Analysis
  • 10.10 Editas Medicine
    • 10.9.1 Company Overview
    • 10.9.2 Company Insights
    • 10.9.3 Business Breakdown
    • 10.9.4 Product Benchmarking
    • 10.9.5 Key Developments
    • 10.9.6 Winning Imperatives
    • 10.9.7 Current Focus & Strategies
    • 10.9.8 Threat from Competition
    • 10.9.9 SWOT Analysis
  • 10.10 Mirus Bio LLC.
    • 10.10.1 Company Overview
    • 10.10.2 Company Insights
    • 10.10.3 Business Breakdown
    • 10.10.4 Product Benchmarking
    • 10.10.5 Key Developments
    • 10.10.6 Winning Imperatives
    • 10.10.7 Current Focus & Strategies
    • 10.10.8 Threat from Competition
    • 10.10.9 SWOT Analysis

11 KEY DEVELOPMENTS

  • 11.1 Product Launches/Developments
  • 11.2 Mergers and Acquisitions
  • 11.3 Business Expansions
  • 11.4 Partnerships and Collaborations

12 APPENDIX

  • 12.1 Related Research